The use of magnetic resonance imaging in multiple sclerosis

Lessons learned from clinical trials

Filippo Martinelli Boneschi, Marco Rovaris, Giancarlo Comi, Massimo Filippi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Magnetic resonance imaging (MRI) is an important paraclinical tool for the diagnosis of multiple sclerosis (MS) and for monitoring its disease course. The efficacy of most of the available MS disease-modifying treatments has been tested in clinical trials where MRI-derived quantities served as primary or secondary outcome measures. However, conventional MRI measures (i.e., the number and volume of contrast-enhancing, the volumes of T2-hyperintense and TI-hypointense lesions and the assessment of brain volume changes) are limited in terms of pathological specificity and, as a consequence, are modestly correlated with clinical measures of disease activity and have a modest prognostic value as predictors of MS evolution. In the present review, we discuss the main factors potentially responsible for the so-called 'clinical MRI paradox' and how modem quantitative MR-based techniques might contribute to, at least partially, overcome it. The lessons learned from MS trials suggest that future applications of MRI to assess MS evolution should rely upon the use of composite measures thought to reflect the various components of the disease, as well as on study protocols specifically designed on the individual trial characteristics.

Original languageEnglish
Pages (from-to)341-347
Number of pages7
JournalMultiple Sclerosis Journal
Volume10
Issue number4
DOIs
Publication statusPublished - Aug 2004

Fingerprint

Multiple Sclerosis
Magnetic Resonance Imaging
Clinical Trials
Modems
Outcome Assessment (Health Care)
Brain

Keywords

  • Clinical trials
  • Magnetic resonance imaging
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The use of magnetic resonance imaging in multiple sclerosis : Lessons learned from clinical trials. / Boneschi, Filippo Martinelli; Rovaris, Marco; Comi, Giancarlo; Filippi, Massimo.

In: Multiple Sclerosis Journal, Vol. 10, No. 4, 08.2004, p. 341-347.

Research output: Contribution to journalArticle

@article{7bddd50268114a269d54f010ba141a06,
title = "The use of magnetic resonance imaging in multiple sclerosis: Lessons learned from clinical trials",
abstract = "Magnetic resonance imaging (MRI) is an important paraclinical tool for the diagnosis of multiple sclerosis (MS) and for monitoring its disease course. The efficacy of most of the available MS disease-modifying treatments has been tested in clinical trials where MRI-derived quantities served as primary or secondary outcome measures. However, conventional MRI measures (i.e., the number and volume of contrast-enhancing, the volumes of T2-hyperintense and TI-hypointense lesions and the assessment of brain volume changes) are limited in terms of pathological specificity and, as a consequence, are modestly correlated with clinical measures of disease activity and have a modest prognostic value as predictors of MS evolution. In the present review, we discuss the main factors potentially responsible for the so-called 'clinical MRI paradox' and how modem quantitative MR-based techniques might contribute to, at least partially, overcome it. The lessons learned from MS trials suggest that future applications of MRI to assess MS evolution should rely upon the use of composite measures thought to reflect the various components of the disease, as well as on study protocols specifically designed on the individual trial characteristics.",
keywords = "Clinical trials, Magnetic resonance imaging, Multiple sclerosis",
author = "Boneschi, {Filippo Martinelli} and Marco Rovaris and Giancarlo Comi and Massimo Filippi",
year = "2004",
month = "8",
doi = "10.1191/1352458504ms1067rr",
language = "English",
volume = "10",
pages = "341--347",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - The use of magnetic resonance imaging in multiple sclerosis

T2 - Lessons learned from clinical trials

AU - Boneschi, Filippo Martinelli

AU - Rovaris, Marco

AU - Comi, Giancarlo

AU - Filippi, Massimo

PY - 2004/8

Y1 - 2004/8

N2 - Magnetic resonance imaging (MRI) is an important paraclinical tool for the diagnosis of multiple sclerosis (MS) and for monitoring its disease course. The efficacy of most of the available MS disease-modifying treatments has been tested in clinical trials where MRI-derived quantities served as primary or secondary outcome measures. However, conventional MRI measures (i.e., the number and volume of contrast-enhancing, the volumes of T2-hyperintense and TI-hypointense lesions and the assessment of brain volume changes) are limited in terms of pathological specificity and, as a consequence, are modestly correlated with clinical measures of disease activity and have a modest prognostic value as predictors of MS evolution. In the present review, we discuss the main factors potentially responsible for the so-called 'clinical MRI paradox' and how modem quantitative MR-based techniques might contribute to, at least partially, overcome it. The lessons learned from MS trials suggest that future applications of MRI to assess MS evolution should rely upon the use of composite measures thought to reflect the various components of the disease, as well as on study protocols specifically designed on the individual trial characteristics.

AB - Magnetic resonance imaging (MRI) is an important paraclinical tool for the diagnosis of multiple sclerosis (MS) and for monitoring its disease course. The efficacy of most of the available MS disease-modifying treatments has been tested in clinical trials where MRI-derived quantities served as primary or secondary outcome measures. However, conventional MRI measures (i.e., the number and volume of contrast-enhancing, the volumes of T2-hyperintense and TI-hypointense lesions and the assessment of brain volume changes) are limited in terms of pathological specificity and, as a consequence, are modestly correlated with clinical measures of disease activity and have a modest prognostic value as predictors of MS evolution. In the present review, we discuss the main factors potentially responsible for the so-called 'clinical MRI paradox' and how modem quantitative MR-based techniques might contribute to, at least partially, overcome it. The lessons learned from MS trials suggest that future applications of MRI to assess MS evolution should rely upon the use of composite measures thought to reflect the various components of the disease, as well as on study protocols specifically designed on the individual trial characteristics.

KW - Clinical trials

KW - Magnetic resonance imaging

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=4344628691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344628691&partnerID=8YFLogxK

U2 - 10.1191/1352458504ms1067rr

DO - 10.1191/1352458504ms1067rr

M3 - Article

VL - 10

SP - 341

EP - 347

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -